OncoTalks | Oncology Insights at Your Fingertips

Micro-Series | Part 4 | DLL3 in EP-NEC: A New Therapeutic Target Comes Into Focus

Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispecific T‑cell engagers.
This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Micro-Series | Part 3 | What’s Next for EP-NEC: New Therapies on the Horizon

With limited durable options available, new approaches are urgently needed in EP-NEC. This episode highlights emerging therapies, including immunotherapy‑based strategies and early clinical trial data shaping future treatment directions.
This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Micro-Series | Part 2 | Treating EP-NEC: What Works, What’s Next

Explore the current EP‑NEC treatment landscape, from first‑line platinum‑based therapy and etoposide to second‑line challenges. Dr. Pelster reviews guideline‑recommended options, sequencing considerations, and why clinical trials are essential in this aggressive disease.
This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Micro-Series | Part 1 | Recognizing EP-NEC: How It Presents and How to Diagnose It

Dr. Meredith Pelster introduces extrapulmonary neuroendocrine carcinoma (EP‑NEC), outlining how patients present and what distinguishes this rare disease. Learn the key elements of diagnostic workup, including pathology, imaging, and features that differentiate EP‑NEC from other neuroendocrine tumors.
This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Navigating Maximum Fair Price in Prostate Cancer Care

In this episode of OncoTalks, host Tulsi Patel speaks with Brandon Dyson, PharmD, BCOP, BCPS, Director of Pharmacy Education at Texas Oncology, about how the Maximum Fair Price (MFP) program may influence prostate cancer care in community oncology. They review therapies selected for MFP regulation, key implementation timelines, and share practical steps oncology providers and practices can take now to prepare.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Sacituzumab Govitecan: Advancing the Role of ADCs in Breast Cancer

In this episode of OncoTalks, host Tulsi Patel speaks with Dr. Hope Rugo about the evolving role of antibody‑drug conjugates (ADCs) in breast cancer, with a focus on sacituzumab govitecan, the first and currently only approved ADC for patients with previously treated metastatic triple‑negative breast cancer (mTNBC). Dr. Rugo highlights key clinical data supporting its approvals in mTNBC and HR‑positive/HER2‑negative disease, and discusses indications, efficacy, safety considerations, and emerging first‑line trial findings that may influence future treatment sequencing.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

From Guidelines to Practice: Navigating Biomarker Testing in NSCLC

In this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing variability in testing practices and emphasize the importance of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Tune in to review the latest clinical guidelines, learn how testing impacts treatment sequencing, and glean insights into how community oncology practices can overcome barriers to ensure that all NSCLC patients receive guideline-concordant testing and treatment.  
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Micro-Series | Part 4 | Future Opportunities to Personalize Multiple Myeloma Care

In the final episode of this four-part series, Dr. Mohit Narang looks ahead to emerging innovations in multiple myeloma. Learn about new therapeutic targets, MRD testing, sequencing strategies, and personalized approaches that aim to optimize outcomes and bring us closer to functional cures.
This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Micro-Series | Part 3 | Real-World Integration of Novel Multiple Myeloma Therapies

In part three of four, Dr. Mohit Narang explores how bispecific antibodies and other advanced treatments are being implemented in real-world community oncology practices. Discover the operational challenges, safety considerations, and strategies that enable community oncology centers to expand access to these transformative therapies for the broader patient population.
This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Micro-Series | Part 2 | Evolution of Multiple Myeloma Treatment

In part two of four, Dr. Mohit Narang examines the rapidly evolving treatment landscape for multiple myeloma. Tune in to learn how therapy has progressed from doublets to quadruplets, reshaping the role of autologous stem cell transplant, and the impact of the latest immune therapies, including monoclonal antibodies, bispecific antibody therapy, and CAR-T approaches.
This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.